AI Article Synopsis
- The study investigates how body mass index (BMI) before lung transplantation affects survival rates after the procedure.
- It categorizes patients into BMI groups (underweight, normal weight, overweight, obese) to evaluate their post-transplant survival.
- Findings suggest that using a BMI cutoff of <17.0 kg/m is crucial for better predicting poor outcomes in underweight patients, rather than the standard <18.5 kg/m cutoff used by the WHO.
Article Abstract
Purpose: The body mass index (BMI) before lung transplantation (LT) is a benchmark of the post-LT survival. The aim of the study is to determine the BMI inadequate for the post-LT survival.
Methods: We examined the survival after LT in patients grouped into the following BMI categories: <18.5 kg/m (underweight), 18.5-24.9 kg/m (normal weight), 25-29.9 kg/m (overweight), and ≥30.0 kg/m (obese) according to the World Health Organization (WHO) criteria. A more detailed categorization was made for further evaluation of the underweight group: mild (17.0 ≤ BMI < 18.5 kg/m) and severely underweight (BMI <17.0 kg/m).
Results: There was no statistically significant difference in the post-LT survival between underweight and normal-weight patients (5-year survival: 78.7 vs. 76.1%). Patients with BMI <17.0 kg/m had a worse prognosis than those with 17.0 ≤ BMI < 18.5 kg/m (5-year survival: 70.3 vs. 90.0%).
Conclusions: Standard BMI categorization per the WHO criteria is inadequate for determining the post-LT survival, especially in underweight patients. For the nutritional evaluation of underweight pre-LT patients, BMI <17.0 kg/m should be used instead of BMI <18.5 kg/m.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-017-1508-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing paediatric and congenital cardiology e-learning postgraduate education: insights from the Association for European Paediatric and Congenital Cardiology directed webinar series.
Cardiol Young
January 2025
Department of Paediatric Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland.
Objective: A series of webinars covering widespread knowledge on paediatric cardiology and cardiac surgery topics was initiated by Association for European Paediatric and Congenital Cardiology, serving towards preparation for the Association for European Paediatric and Congenital Cardiology certification in paediatric and congenital cardiology. This study investigated the impact of webinars as educational tools for junior paediatric cardiologists in the post-COVID-19 pandemic era.
Materials And Methods: A cross-sectional survey design study using an online survey as a tool for the assessment of trainees.
PBAE-PEG based lipid nanoparticles for lung cell-specific gene delivery.
Mol Ther
January 2025
Perinatal Institute, Division of Neonatology, Perinatal and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA. Electronic address:
Exemplified by successful use in COVID-19 vaccination, delivery of modified mRNA encapsulated in lipid nanoparticles provides a framework for treating various genetic and acquired disorders. However, lipid nanoparticles that can deliver mRNA into specific lung cell types have not yet been established. Here, we sought whether poly(®-amino ester)s (PBAE) or PEGylated PBAE (PBAE-PEG) in combination with 4A3-SC8/DOPE/cholesterol/DOTAP lipid nanoparticles (LNP) could deliver mRNA into different types of lung cells in vivo.
View Article and Find Full Text PDFCharacterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.
Cancer Med
February 2025
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.
Methods: Between 12/2019 and 06/2022, 237 patients were included.
Migrasomes derived from human umbilical cord mesenchymal stem cells: a new therapeutic agent for ovalbumin-induced asthma in mice.
Stem Cell Res Ther
January 2025
Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212000, Jiangsu, P. R. China.
Background: Asthma is a prevalent respiratory disease, and its management remains largely unsatisfactory. Mesenchymal stem cells (MSCs) have been demonstrated to be efficacious in reducing airway inflammation in experimental allergic diseases, representing a potential alternative treatment for asthma. Migrasomes are recently identified extracellular vesicles (EVs) generated in migrating cells and facilitate intercellular communication.
View Article and Find Full Text PDFEarly Renal Failure After Primary Thoracic Organ Transplantation.
J Heart Lung Transplant
January 2025
The International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry, Chicago, IL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!